0000899243-23-002434.txt : 20230123 0000899243-23-002434.hdr.sgml : 20230123 20230123183553 ACCESSION NUMBER: 0000899243-23-002434 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: de los Pinos Elisabet CENTRAL INDEX KEY: 0001889633 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 23545514 MAIL ADDRESS: STREET 1: C/O AURA BIOSCIENCES, INC. STREET 2: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 01235 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 01235 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-19 0 0001501796 Aura Biosciences, Inc. AURA 0001889633 de los Pinos Elisabet C/O AURA BIOSCIENCES, INC. 80 GUEST STREET BOSTON MA 01235 1 1 0 0 See Remarks Common Stock 2023-01-19 4 A 0 121875 0.00 A 190526 D Common Stock 131412 I By EdIP Revocable Trust Stock Option (Right to Buy) 10.18 2023-01-19 4 A 0 187500 A 2033-01-18 Common Stock 187500 187500 D These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. President and Chief Executive Officer /s/ Julie Feder, as Attorney-in-Fact 2023-01-23